Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Conference Call March 24, 2023 4:30 PM ET

Company Participants

Raju Mohan - Founder & Chief Executive Officer

Marty Auster - Chief Financial Officer

Bill Sandborn - President & Chief Medical Officers

Conference Call Participants

Michael Yee - Jefferies

Yasmeen Rahimi - Piper Sandler

Jeff Jones - Oppenheimer

Chris Shibutani - Goldman Sachs

Emily Bodnar - H.C. Wainwright & Co

Operator

Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time all participants have been placed on a listen-only mode, and the floor will be open for your questions following the presentation. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Dr. Marty Auster, Ventyx's Chief Financial Officer. You may begin.

Marty Auster

Thank you, Chelsea. Good afternoon, everyone. Thanks for joining us today. Welcome to Ventyx’s Biosciences conference call and webcast, where we will be discussing our fourth quarter and full year 2022 financial results and providing a business update. As a reminder, the company's most recent investor presentation can be found on our website at www.ventyxbio.com, under the Investors tab in the News & Events section.

Before we begin today, I’d would like to remind everyone that, this conference call and webcast will contain forward-looking statements about the company, including without limitation statements about the anticipated timing of commencement, enrollment and completion of clinical trials, the anticipated timing of release of clinical trial data, the market opportunity for our product candidates, and the expected time frame for funding operations with current cash equivalents and marketable securities.

These statements are subject to risks and uncertainties that could cause actual results to differ. Factors that could cause actual results or outcomes to differ materially from those expressed and/or implied by such forward-looking statements are discussed in greater detail in our most recent reports filed with the SEC, including our Form 10-K for the year ended December 31, 2022 which will be filed this afternoon.

Please note that these forward-looking statements reflect our opinions only as of the date of this call and we undertake no obligation to revise or publicly release the results of any revisions to these forward-looking statements, in light of new information or future events, except as required by law.

With that said, I'll hand the call now over to Dr. Raju Mohan, Ventyx's Founder and CEO. Raju, please go ahead.